Clinical trial
68Ga/177Lu-PSMA Theranostics in Recurrent Grade 3 and Grade 4 Glioma
NCT05644080 is registered in ClinicalTrials.gov with St. Olavs Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- 68Ga/177Lu-PSMA Theranostics in Recurrent Grade 3 and Grade 4 Glioma
- Lead sponsor
- St. Olavs Hospital
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- March 28, 2023
- Completion date
- July 17, 2025
- Enrollment
- 10 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
high grade glioma